Vericel Corporation (VCEL)
POSITIVEFundamental
70
Price
$42.91
Market Cap
$2.20B
Part 1 · What the company is worth
Overview
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$306M
Trailing 12 months (through 6/30/2026)
Net Income
$24M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$25M
Total Equity
$355M
Total Liabilities
$133M
Current Ratio
5.04
Interest Coverage
28.49
Debt/EBITDA
4.12
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$44.40
Current Price
$42.91
Margin of Safety
+3.4%
Fair Value Range
$30.48 - $58.33
Estimation Methods
Valuation Metrics
P/E Ratio
88.13
ROE
4.7%
P/B Ratio
5.85
P/FCF
35.13
Gross Margin
74.6%
ROIC
3.2%
Profitability Radar
Value Creation (Economic Moat)
ROIC
3.2%
WACC
9.8%
ROIC − WACC
-6.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (19)
- EPS shows upward trend
- Price CAGR 30.41%
- Gross Margin 74.6%
- Debt/Equity ratio
- Operating Margin 6.0%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Revenue Growth 5Y 17.3%
- Analyst Consensus 86% Buy
- Earnings Surprise avg 484.8%
- Earnings Quality (OCF/NI) 2.88
- Share Dilution -0.4%
- Net Margin Trend 7.9% vs 2.9%
- Piotroski F-Score 9/9
Failed (7)
- ROIC 3.2%
- P/FCF 35.13
- P/B Ratio 5.85
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 6.9%
- PEG Ratio 2.40
Unavailable (1)
- Dividend Payout NaN%
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Dominick C. Colangelo Esq. | CEO, President & Director | 61 |
| Mr. Joseph Anthony Mara Jr. | CFO & Treasurer | 49 |
| Mr. Michael Halpin | Chief Operating Officer | 63 |
| Mr. Sean C. Flynn | Chief Legal Officer | 51 |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer | 63 |
| Mr. Jonathan D. Siegal | Principal Accounting Officer, VP & Corporate Controller | - |
| Mr. Eric Burns | Vice President of Finance & Investor Relations | - |
| Mr. Roland DeAngelis | Chief Marketing Officer | - |
| Mr. Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | - |
| Mr. Mike Gilligan | Senior Vice President of Sales | - |
Audit Risk
4
Board Risk
3
Compensation Risk
6
Shareholder Rights Risk
4
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for VCEL, sourced from Markets Gazette.
- 2/26/2026NEUTRALVericel (VCEL) Q4 2025 Earnings Call Transcript
Biotechnology firm Vericel (VCEL) held its fourth-quarter 2025 earnings conference call. While specific details from the transcript are not yet available, this event is crucial for investors monitoring the company's financial performance and future outlook. Earnings calls are key moments to assess operational health, revenues, profit margins, and management's guidance. The immediate lack of information prevents an in-depth analysis, but the market will keenly await the data release to understand the impact on key products like MACI and Epicel. Investors should remain vigilant for subsequent communications that could influence the stock's valuation.
via Markets Gazette